Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Metastatic Castration Resistant Prostate Cancer Metastatic Cancer mCRPC Immunotherapy CDK12 Prostatic Neoplasms Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Nivolumab Ipilimumab Metastatic CRPC Solid Tumors (non-prostate)
Lead Scientist at UCSF
- Jonathan Chou, M.D., Ph.D.
I am a physician-scientist broadly interested in translational oncology and am currently an Instructor in the Division of Hematology/Oncology and postdoctoral research fellow in the Feng Lab (http://fenglaboratory.com/) and Ashworth Lab.
- accepting new patients
- Start Date
- Completion Date
- University of Michigan Rogel Cancer Center
- Phase 2 research study
- Study Type
- Expecting 40 study participants
- Last Updated